PET/CT Imaging of Unstable Carotid Plaque with Ga-Labeled Somatostatin Receptor Ligand
Overview
Authors
Affiliations
Ga-labeled somatostatin receptor ligand PET imaging has recently been shown in preclinical and early human studies to have a potential role in the evaluation of vulnerable arterial plaques. We prospectively evaluated carotid plaque Ga-DOTATATE uptake in patients with recent carotid events, assessed inter- and intraobserver variability of such measurements, and explored the mechanism of any plaque DOTATATE activity with immunohistochemistry in resected specimens. Twenty consecutively consenting patients with recent symptomatic carotid events (transient ischemic attack, stroke, or amaurosis fugax), due for carotid endarterectomy, were prospectively recruited. Ga-DOTATATE PET/CT of the neck was performed before surgery. Ga-DOTATATE uptake was measured by drawing regions of interest along the carotid plaques and contralateral plaques/carotid arteries by an experienced radionuclide radiologist and radiographer. Two PET quantification methods with inter- and intraobserver variability were assessed. Resected carotid plaques were retrieved for somatostatin receptor subtype-2 (sst2) immunohistochemical staining. The median time delay between research PET and surgery was 2 d. SUVs and target-to-background ratios for the symptomatic plaques and the asymptomatic contralateral carotid arteries/plaques showed no significant difference ( = 19, > 0.10), regardless of quantification method. The intraclass correlation coefficient was greater than 0.8 in all measures of carotid artery/plaque uptake (SUV) and greater than 0.6 in almost all measures of target-to-background ratio. None of the excised plaques was shown to contain cells (macrophages, lymphocytes, vessel-associated cells) expressing sst2 on their cell membrane. Ga-DOTATATE activity on PET in recently symptomatic carotid plaques is not significantly different from contralateral carotids/plaques. Any activity seen on PET is not shown to be from specific sst2 receptor-mediated uptake in vitro. It is therefore unlikely that sst2 PET/CT imaging will have a role in the detection and characterization of symptomatic carotid plaques.
Estimating inflammatory risk in atherosclerotic cardiovascular disease: plaque over plasma?.
Annink M, Kraaijenhof J, Beverloo C, Oostveen R, Verberne H, Stroes E Eur Heart J Cardiovasc Imaging. 2024; 26(3):444-460.
PMID: 39657321 PMC: 11879196. DOI: 10.1093/ehjci/jeae314.
Rubinstein G, Ilhan H, Bartenstein P, Lehner S, Hacker M, Todica A Diagnostics (Basel). 2024; 14(22).
PMID: 39594152 PMC: 11593158. DOI: 10.3390/diagnostics14222486.
Identification of vulnerable carotid plaque with histologically validated CT-derived plaque maps.
Obaid D, Okonji I, Cheng S, Giannopoulos A, Kamalathevan P, Halcox J Br J Radiol. 2023; 96(1147):20220982.
PMID: 37183910 PMC: 10321253. DOI: 10.1259/bjr.20220982.
Toner Y, Ghotbi A, Naidu S, Sakurai K, van Leent M, Jordan S Sci Rep. 2022; 12(1):6185.
PMID: 35418569 PMC: 9007951. DOI: 10.1038/s41598-022-09590-2.
Current advances in the imaging of atherosclerotic vulnerable plaque using nanoparticles.
Zhang M, Xie Z, Long H, Ren K, Hou L, Wang Y Mater Today Bio. 2022; 14:100236.
PMID: 35341094 PMC: 8943324. DOI: 10.1016/j.mtbio.2022.100236.